Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approachesOmima S. Mohammed, Hany M. Fayed, Hany G. Attia et al.|Journal of Pharmacy & Pharmaceutical Sciences|2023Cited by 39
Nrf2/<scp>HO</scp>‐1, <scp>NF‐κB</scp> and <scp>PI3K</scp>/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in ratsMarawan A. Elbaset, Hany M. Fayed, Bassim M. S. A. Mohamed et al.|Journal of Cellular and Molecular Medicine|2024Cited by 32
Erythropoietin mitigated thioacetamide-induced renal injury via JAK2/STAT5 and AMPK pathwayMarawan A. Elbaset, Hany M. Fayed, Bassim M. S. A. Mohamed et al.|Scientific Reports|2023Cited by 27
Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling PathwaysMarawan A. Elbaset, Hany M. Fayed, Dina F. Mansour et al.|Oxidative Medicine and Cellular Longevity|2023Cited by 24
Repositioning gemigliptin for the alleviation of thioacetamide-induced liver fibrosis in rats: Targeting TLR4/MAPK, SIRT1/AMPK/Nrf2, PI3K/AKT/mTOR axis and apoptosisRiyadh S. Almalki, Marawan A. Elbaset, Malaz Gazzaz et al.|European Journal of Pharmaceutical Sciences|2025Cited by 15